Enhanced Delivery and Bioactivity of the Neurturin Neurotrophic Factor through Focused Ultrasound—Mediated Blood—Brain Barrier Opening in vivo

The blood—brain barrier (BBB) constitutes a major obstacle in brain drug delivery. Focused ultrasound (FUS) in conjunction with microbubbles has been shown to open the BBB noninvasively, locally, and transiently to allow large molecules diffusion. Neurturin (NTN), a member of the glial-derived neurotrophic factor (GDNF) family, has been demonstrated to have neuroprotective and regenerative effects on dopaminergic neurons in vivo using invasive drug delivery methods. The brain's ascending nigrostriatal pathway is severely damaged in Parkinson's disease (PD), and therefore the substantia nigra (SN) and striatal caudoputamen (CP) were selected as the target areas. The objective of the study was to investigate whether safe and efficient NTN delivery can be achieved through FUS-induced BBB opening via intravenous administration, and thus trigger the neuroregeneration cascade in the nigrostriatal pathway. After the optimization of FUS parameters and target locations in the murine brain, NTN bioavailability and downstream signaling were detected and characterized through immunostaining. FUS significantly enhanced the delivery of NTN compared with the direct injection technique, whereas triggering of the signaling cascade was detected downstream to the neuronal nuclei. These findings thus indicate the potential of the FUS method to mediate transport of proteins through the blood—brain barrier in a PD animal model.

[1]  Jameel A Feshitan,et al.  Microbubble size isolation by differential centrifugation. , 2009, Journal of colloid and interface science.

[2]  Elisa E. Konofagou,et al.  Dependence of the reversibility of focused- ultrasound-induced blood-brain barrier opening on pressure and pulse length in vivo , 2013, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control.

[3]  N. McDannold,et al.  Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[4]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[5]  K. Hynynen,et al.  Ultrasound Enhanced Delivery of Molecular Imaging and Therapeutic Agents in Alzheimer's Disease Mouse Models , 2008, PloS one.

[6]  James J. Choi,et al.  Activation of signaling pathways following localized delivery of systemically administered neurotrophic factors across the blood–brain barrier using focused ultrasound and microbubbles , 2012, Physics in medicine and biology.

[7]  G. Gerhardt,et al.  Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. , 2005, Journal of neurosurgery.

[8]  Kullervo Hynynen,et al.  Targeted Delivery of Neural Stem Cells to the Brain Using MRI-Guided Focused Ultrasound to Disrupt the Blood-Brain Barrier , 2011, PloS one.

[9]  T. Yen,et al.  Noninvasive and Targeted Gene Delivery into the Brain Using Microbubble-Facilitated Focused Ultrasound , 2013, PloS one.

[10]  B. Hoffer,et al.  Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.

[11]  A. Björklund,et al.  Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle , 1999, The European journal of neuroscience.

[12]  Yao-Sheng Tung,et al.  A quantitative pressure and microbubble‐size dependence study of focused ultrasound‐induced blood‐brain barrier opening reversibility in vivo using MRI , 2012, Magnetic resonance in medicine.

[13]  J. Jankovic,et al.  Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD , 2003, Neurology.

[14]  G. Gerhardt,et al.  Intraputamenal Infusion of Exogenous Neurturin Protein Restores Motor and Dopaminergic Function in the Globus Pallidus of MPTP-Lesioned Rhesus Monkeys , 2008, Cell transplantation.

[15]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[16]  D. Brooks,et al.  Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.

[17]  G. Gerhardt,et al.  Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys , 2002, Neurobiology of Aging.

[18]  Mu-Yi Hua,et al.  Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. , 2010, Radiology.

[19]  Yau-Yau Wai,et al.  Hemorrhage detection during focused-ultrasound induced blood-brain-barrier opening by using susceptibility-weighted magnetic resonance imaging. , 2008, Ultrasound in medicine & biology.

[20]  Yi Ai,et al.  Trophic factor distribution predicts functional recovery in parkinsonian monkeys , 2005, Annals of neurology.

[21]  Mark Stacy,et al.  Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease , 2006, Annals of neurology.

[22]  Mickael Tanter,et al.  Dynamic Study of Blood–Brain Barrier Closure after its Disruption using Ultrasound: A Quantitative Analysis , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  W. Pardridge The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[24]  T. Itakura,et al.  Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson’s disease , 2002, Brain Research.

[25]  Win-Li Lin,et al.  Quantitative evaluation of focused ultrasound with a contrast agent on blood-brain barrier disruption. , 2007, Ultrasound in medicine & biology.

[26]  V. Ferrera,et al.  Noninvasive, Transient and Selective Blood-Brain Barrier Opening in Non-Human Primates In Vivo , 2011, PloS one.

[27]  James J. Choi,et al.  Noninvasive, transcranial and localized opening of the blood-brain barrier using focused ultrasound in mice. , 2007, Ultrasound in medicine & biology.

[28]  E. Konofagou,et al.  Permeability assessment of the focused ultrasound-induced blood–brain barrier opening using dynamic contrast-enhanced MRI , 2010, Physics in medicine and biology.

[29]  Jie Shi,et al.  Targeted Delivery of GDNF through the Blood–Brain Barrier by MRI-Guided Focused Ultrasound , 2012, PloS one.

[30]  Mark Borden,et al.  Microbubble Compositions, Properties and Biomedical Applications. , 2009, Bubble science engineering and technology.

[31]  Richard Grondin,et al.  Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. , 2002, Brain : a journal of neurology.

[32]  Natalia Vykhodtseva,et al.  Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI‐guided focused ultrasound , 2007, International journal of cancer.

[33]  A. Ruifrok,et al.  Quantification of histochemical staining by color deconvolution. , 2001, Analytical and quantitative cytology and histology.

[34]  K. Hynynen,et al.  Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. , 2001, Radiology.

[35]  木下 学 Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption , 2007 .

[36]  K. Bankiewicz,et al.  Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain , 2010, Neuropharmacology.

[37]  L. Rubin,et al.  The cell biology of the blood-brain barrier. , 1999, Annual review of neuroscience.

[38]  A. Lang,et al.  Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients , 2013, Neurology.

[39]  S. Gill,et al.  Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study , 2005, Annals of neurology.

[40]  E. Mufson,et al.  Bioactivity of AAV2‐neurturin gene therapy (CERE‐120): Differences between Parkinson's disease and nonhuman primate brains , 2011, Movement disorders : official journal of the Movement Disorder Society.

[41]  R. Bakay,et al.  Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys , 2006, Annals of neurology.

[42]  M. Hennerici,et al.  Focal delivery of AAV2/1-transgenes into the rat brain by localized ultrasound-induced BBB Opening. , 2014, Annals of neurosciences.

[43]  P. Tofts,et al.  Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.